吡格列酮研究进展资料讲解.pptVIP

盐酸吡格列酮研究进展;;;吡格列酮对于伴有中风病史或不伴有中风病史患者的作用— PROactive研究亚组分析结果;入组标准：大血管疾病病史 ;到致死性中风或非致死性中风的时间;结论;IRIS－研究目的;IRIS－研究设计;CHICAGO;研究目的和设计;研究设计;研究终点;CIMT的测量;;p=0.01;-0.010;72周(LOCF)时远壁CIMT最大值与基线相比的变化;;Baseline; HDL-C与基线相比的变化 (mg/dL);其他血脂和血压的影响;小结;来自19个临床研究的16,390患者分析;结论：吡格列酮显著降低心血管事件;单用吡格列酮显著改善胰岛素指标;空腹血糖;联合应用吡格列酮显著降低HbA1c /FPG;;;吡格列酮改善2型糖尿病患者高血压;单用吡格列酮显著降低尿白蛋白/肌酐比值;吡格列酮显著降低C反应蛋白;抑制平滑肌增殖、降低CIMT;吡格列酮逆转动脉硬化、消退斑块;内 容;PROactive-CKD分析;;;内 容;吡格列酮与格列美脲对2型糖尿???冠脉硬  化进展的作用比较(PERISCOPE);背景与目的;方 法;基线资料 (n=543);基线治疗(n=543);基线实验检查与血压*;HbAlc 变化;血压变化(n = 360);血生化改变的百分比;动脉斑块体积变化(PAV) (%);血管内超声: 次极终点;;;调整后的CVD事件;Other Adverse Effects;PERISCOPE:与其他试验比较;结论;实验室数值与BP的变化;Other Biomarkers: Insulin Levels and BNP;Actos Now for Prevention of Diabetes (ACT NOW);Dr. Ralph DeFronzo, professor of medicine at the Health Science Center and deputy director of the Texas Diabetes Institute, said the trial should demonstrate pioglitazone’s ability to improve the body’s sensitivity to insulin and prevent insulin-producing beta cells from dying.Dr. DeFronzo is principal investigator for the ACT NOW Trial (Actos Now for the Prevention of Type 2 Diabetes), which will compare outcomes of pre-diabetic individuals receiving pioglitazone with those receiving a placebo.;Actos Now for Prevention of Diabetes (ACT NOW) ADA 2008;Pioglitazone Prevents Conversion to Diabetes Among Insulin-Resistant Patients: Presented at ADA ; IGT n = 602 ---- 407 IGT+IFG ----195 I-IGT;; Thank You